AgingResearch.NewsJoin free

Norcantharidin

Norcantharidin has been studied in 1 paper since 2022: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Nov 3, 2022: “Norcantharidin ameliorates estrogen deficient-mediated bone loss by attenuating the activation of extracellular signal-regulated kinase/ROS/NLRP3 inflammasome signaling”.

Intervention

1 paper studies it1 findingUpdated

PubChem

See all 1 papers on norcantharidin

At a glance

The findings reach mice, none yet in people. 1 lab in 1 country.

Mice: a single group. Cells, worms or flies and humans: nothing yet.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

  • 1 lab in 1 country
  • Funders: China Postdoctoral Science Foundation and 2 more
  • Animals1

What did studies of norcantharidin find?

1

Studies of norcantharidin measured one outcome, estrogen-deficiency bone loss.

Estrogen-deficiency bone loss

downin N. stated1

1 study

  1. Norcantharidin prevents estrogen-deficiency bone loss in N. stated (estrogen-deficiency model).

    “our in vivo study further confirms its preventive effects on estrogen-deficiency bone loss by inhibiting osteoclast formation and functions”

    Animalsestrogen-deficiency modelbone

    Norcantharidin ameliorates estrogen deficient-mediated bone loss by attenuating the activation of extracellular signal-regulated kinase/ROS/NLRP3 inflammasome signaling

    Frontiers in pharmacology

More on Estrogen-deficiency bone loss

Latest

Related